Preferred Label : ruxolitinib;
UMLS semantic type : T109 - Organic Chemical; T121 - Pharmacologic Substance;
Is substance : O;
Origin ID : M0549299;
UMLS CUI : C2931926;
CISMeF manual mappings
- Manual BTNT mappings - CISMeF
- MeSH narrower concept(s)
- Related record
- See also inter- (CISMeF)
- Semantic type(s)
- UMLS correspondences (same concept)
- Validated automatic mappings to BTNT
https://www.inesss.qc.ca/publications/repertoire-des-publications/publication/dosage-sanguin-du-ruxolitinib-par-chromatographie-liquide-de-haute-performance-couplee-a-la-spectrometrie-de-masse-en-tandem-hplc-ms-ms.html
2024
Canada
health technology assessment
chromatography measurement, nos
couples
liquid substance, nos
chromatography
ruxolitinib
ruxolitinib
mass, nos
family characteristics
chromatography, high pressure liquid
tandem mass spectrometry
---
https://www.has-sante.fr/jcms/p_3331384/fr/jakavi-ruxolitinib-maladie-du-greffon
2022
false
false
false
France
French
evaluation of the transparency committee
transplants
transplant, nos
disease
ruxolitinib
disease, nos
ruxolitinib
Diseases
Diseases Category
Disease
---
https://www.oncorif.fr/wp-content/uploads/2019/05/Jakavi_patient.pdf
2019
false
false
false
false
France
French
guidelines for drug use
patients guideline
ruxolitinib
ruxolitinib
pyrazoles
tablets
tablets
---
http://www.has-sante.fr/portail/jcms/c_2608680/fr/jakavi
2016
false
France
French
Ruxolitinib Phosphate
Post essential thrombocythemia myelofibrosis
Post polycythemia vera myelofibrosis
Tyrosine Kinase Inhibitors
administration, oral
insurance, health, reimbursement
ruxolitinib
orphan drug production
treatment outcome
splenomegaly
splenomegaly
ruxolitinib
ruxolitinib
janus kinases
ruxolitinib
ruxolitinib
primary myelofibrosis
evaluation of the transparency committee
pyrazoles
pyrazoles
---
http://www.has-sante.fr/portail/jcms/c_2658531/fr/jakavi
http://www.has-sante.fr/portail/jcms/c_2658531/fr/jakavi-ruxolitinib-inhibiteur-de-proteine-kinase
2016
false
France
French
Ruxolitinib Phosphate
Post essential thrombocythemia myelofibrosis
polycythemia vera
Post polycythemia vera myelofibrosis
thrombocythemia, essential
guidelines for drug use
Tyrosine Kinase Inhibitors
administration, oral
insurance, health, reimbursement
ruxolitinib
orphan drug production
treatment outcome
splenomegaly
ruxolitinib
janus kinases
ruxolitinib
primary myelofibrosis
evaluation of the transparency committee
pyrazoles
---
http://www.e-cancer.fr/Expertises-et-publications/Catalogue-des-publications/Medicaments-ciblant-BCR-ABL-Imatinib-Dasatinib-Nilotinib-Bosutinib-Ponatinib-Medicament-ciblant-JAK-Ruxolitinib-Anticancereux-par-voie-orale-informer-prevenir-et-gerer-leurs-effets-indesirables
2016
false
false
false
France
French
practice guideline
antineoplastic agents
administration, oral
Drug-Related side effects and adverse reactions
Drug-Related side effects and adverse reactions
information dissemination
patient education as topic
drug interactions
Dasatinib
Imatinib Mesylate
fusion proteins, bcr-abl
protein kinase inhibitors
dasatinib
imatinib
nilotinib
nilotinib
bosutinib
ponatinib
ruxolitinib
janus kinases
ponatinib
ruxolitinib
bosutinib
continuity of patient care
pregnancy
Tyrosine Kinase Inhibitors
nilotinib
ruxolitinib
aniline compounds
nitriles
quinolines
imidazoles
pyridazines
pyrimidines
pyrazoles
---
http://www.has-sante.fr/portail/jcms/c_2580831/fr/jakavi
http://www.has-sante.fr/portail/jcms/c_2580831/fr/jakavi-ruxolitinib-inhibiteur-de-proteine-kinase-progres-therapeutique-mineur-en-deuxieme-ligne-de-traitement-de-la-polyglobulie-de-vaquez
2015
false
France
French
polycythemia vera
guidelines for drug use
Tyrosine Kinase Inhibitors
administration, oral
insurance, health, reimbursement
ruxolitinib
treatment outcome
ruxolitinib
ruxolitinib
janus kinases
ruxolitinib
ruxolitinib
evaluation of the transparency committee
pyrazoles
pyrazoles
---
http://www.e-cancer.fr/content/download/126025/1524695/file/Médicaments%20ciblant%20BCR-ABL.pdf
2015
false
false
false
France
French
practice guideline
guidelines for drug use
administration, oral
antineoplastic agents
Drug-Related side effects and adverse reactions
imatinib
dasatinib
nilotinib
nilotinib
bosutinib
bosutinib
ponatinib
ponatinib
protein kinase inhibitors
ruxolitinib
ruxolitinib
janus kinases
information dissemination
continuity of patient care
hospital-physician relations
hospital-patient relations
physician-patient relations
drug interactions
pregnancy
protein-tyrosine kinases
Tyrosine Kinase Inhibitor
Dasatinib
Imatinib Mesylate
Tyrosine Kinase Inhibitors
nilotinib
ruxolitinib
pyrazoles
aniline compounds
nitriles
quinolines
imidazoles
pyridazines
---
http://www.has-sante.fr/portail/jcms/c_1359739/jakavi
http://www.has-sante.fr/portail/jcms/c_1651869/fr/jakavi
2013
false
France
French
guidelines for drug use
Tyrosine Kinase Inhibitors
administration, oral
insurance, health, reimbursement
ruxolitinib
orphan drug production
treatment outcome
randomized controlled trials as topic
splenomegaly
splenomegaly
ruxolitinib
ruxolitinib
janus kinases
ruxolitinib
ruxolitinib
primary myelofibrosis
evaluation of the transparency committee
survival analysis
clinical trials, phase iii as topic
pyrazoles
pyrazoles
---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=66180136
2013
summary of product characteristics
ruxolitinib
phosphates
tablets
---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=65291824
2013
summary of product characteristics
phosphates
tablets
ruxolitinib
---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=60672974
2013
summary of product characteristics
phosphates
tablets
ruxolitinib
---
https://www.ema.europa.eu/medicines/human/EPAR/Jakavi
2012
false
France
French
Tyrosine Kinase Inhibitors
ruxolitinib
ruxolitinib
drug approval
europe
treatment outcome
ruxolitinib
ruxolitinib
summary of product characteristics
package leaflet
drug evaluation
syndication feed
orphan drug production
administration, oral
adult
primary myelofibrosis
splenomegaly
primary myelofibrosis
janus kinase 1
protein kinase inhibitors
protein kinase inhibitors
drug interactions
pregnancy
breast feeding
janus kinase 2
clinical trials, phase iii as topic
drug evaluation, preclinical
thrombocythemia, essential
polycythemia vera
pyrazoles
pyrazoles
ruxolitinib
---
Summary Basis of Decision (SBD) for Jakavi
Ruxolitinib, as ruxolitinib phosphate, 5 mg, 15 mg, and 20 mg, Tablet, Oral
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailOne.php?lang=fr&linkID=SBD00079
2012
false
Canada
French
English
drug information
Ruxolitinib 5mg tablet (product)
Product containing precisely ruxolitinib 15 milligram/1 each conventional release
oral tablet (clinical drug)
Product containing precisely ruxolitinib 20 milligram/1 each conventional release
oral tablet (clinical drug)
Tyrosine Kinase Inhibitors
administration, oral
ruxolitinib
ruxolitinib
ruxolitinib
ruxolitinib
ruxolitinib
antineoplastic agents
antineoplastic agents
janus kinase 1
janus kinase 2
protein kinase inhibitors
protein kinase inhibitors
adult
splenomegaly
primary myelofibrosis
drug evaluation, preclinical
treatment outcome
clinical trials, phase ii as topic
clinical trials, phase iii as topic
risk assessment
drug approval
canada
pyrazoles
pyrazoles
---
